Sarepta Therapeutics, Inc.

DB:AB3A Stock Report

Market Cap: €11.7b

Sarepta Therapeutics Valuation

Is AB3A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AB3A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€345.53
Fair Value
64.4% undervalued intrinsic discount
21
Number of Analysts

Below Fair Value: AB3A (€123) is trading below our estimate of fair value (€345.53)

Significantly Below Fair Value: AB3A is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AB3A?

Key metric: As AB3A is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for AB3A. This is calculated by dividing AB3A's market cap by their current earnings.
What is AB3A's PE Ratio?
PE Ratio99x
EarningsUS$121.85m
Market CapUS$12.06b

Price to Earnings Ratio vs Peers

How does AB3A's PE Ratio compare to its peers?

The above table shows the PE ratio for AB3A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average64.3x
BIO3 Biotest
15.8x29.3%€1.4b
FYB Formycon
17.3x22.6%€1.1b
SRT3 Sartorius
210.6x30.1%€14.7b
2INV 2invest
13.5xn/a€67.8m
AB3A Sarepta Therapeutics
99x31.9%€12.1b

Price-To-Earnings vs Peers: AB3A is expensive based on its Price-To-Earnings Ratio (99x) compared to the peer average (63.8x).

Price to Earnings Ratio vs Industry

How does AB3A's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
AB3A 99.0xIndustry Avg. 28.3xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: AB3A is expensive based on its Price-To-Earnings Ratio (99x) compared to the European Biotechs industry average (28.8x).

Price to Earnings Ratio vs Fair Ratio

What is AB3A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AB3A PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio99x
Fair PE Ratio26.5x

Price-To-Earnings vs Fair Ratio: AB3A is expensive based on its Price-To-Earnings Ratio (99x) compared to the estimated Fair Price-To-Earnings Ratio (26.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AB3A forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€123.00
€179.57
+46.0%
17.1%€212.67€72.83n/a21
Jan ’26€115.95
€178.67
+54.1%
16.8%€210.42€72.06n/a21
Dec ’25€130.10
€173.99
+33.7%
17.1%€207.28€75.72n/a22
Nov ’25€115.25
€175.61
+52.4%
12.3%€203.43€136.04n/a21
Oct ’25€111.50
€176.42
+58.2%
10.2%€199.69€134.34n/a19
Sep ’25€123.45
€176.05
+42.6%
10.2%€200.07€134.59n/a20
Aug ’25€131.00
€182.91
+39.6%
11.3%€216.79€136.53n/a21
Jul ’25€146.35
€184.84
+26.3%
13.0%€219.58€123.21n/a22
Jun ’25€119.55
€153.93
+28.8%
13.4%€206.48€117.99n/a22
May ’25€119.70
€154.04
+28.7%
14.3%€209.51€119.72n/a20
Apr ’25€119.60
€150.93
+26.2%
14.1%€205.74€117.57n/a21
Mar ’25€116.05
€151.73
+30.7%
14.2%€206.71€118.12n/a21
Feb ’25€110.05
€136.57
+24.1%
20.5%€207.31€95.33n/a21
Jan ’25€88.08
€122.73
+39.3%
26.4%€202.38€72.28€115.9520
Dec ’24€74.08
€127.22
+71.7%
27.7%€204.69€73.10€130.1018
Nov ’24€68.64
€130.81
+90.6%
30.4%€208.19€37.85€115.2517
Oct ’24€116.65
€171.58
+47.1%
12.6%€210.56€131.24€111.5018
Sep ’24€111.40
€164.34
+47.5%
13.5%€204.20€127.28€123.4519
Aug ’24€98.08
€162.05
+65.2%
13.4%€199.21€125.29€131.0018
Jul ’24€102.80
€164.00
+59.5%
13.1%€200.15€127.62€146.3519
Jun ’24€115.25
€165.63
+43.7%
12.2%€203.20€129.56€119.5520
May ’24€110.35
€155.43
+40.9%
11.4%€186.95€126.14€119.7018
Apr ’24€124.22
€157.13
+26.5%
11.6%€189.91€128.14€119.6018
Mar ’24€133.68
€158.36
+18.5%
14.5%€211.97€117.24€116.0519
Feb ’24€114.18
€137.47
+20.4%
14.2%€179.38€99.35€110.0518
Jan ’24€118.56
€136.77
+15.4%
14.8%€178.05€94.65€88.0820
Analyst Price Target
Consensus Narrative from 21 Analysts
€180.12
Fair Value
31.7% undervalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 19:43
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sarepta Therapeutics, Inc. is covered by 53 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Huidong WangBarclays
Zhiqiang ShuBerenberg